17.31
Schlusskurs vom Vortag:
$17.20
Offen:
$17.7
24-Stunden-Volumen:
49,179
Relative Volume:
1.97
Marktkapitalisierung:
$131.75M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-61.23M
KGV:
-1.2804
EPS:
-13.5194
Netto-Cashflow:
$22.49M
1W Leistung:
+0.99%
1M Leistung:
+28.03%
6M Leistung:
+17.60%
1J Leistung:
+12.40%
Assembly Biosciences Inc Stock (ASMB) Company Profile
Firmenname
Assembly Biosciences Inc
Sektor
Branche
Telefon
(833) 409-4583
Adresse
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Vergleichen Sie ASMB mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
ASMB
Assembly Biosciences Inc
|
17.31 | 131.75M | 0 | -61.23M | 22.49M | -13.52 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
520.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
321.82 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
267.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-25 | Eingeleitet | Guggenheim | Buy |
2024-09-20 | Hochstufung | Jefferies | Hold → Buy |
2021-09-13 | Eingeleitet | H.C. Wainwright | Neutral |
2021-09-02 | Herabstufung | William Blair | Outperform → Mkt Perform |
2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
2020-11-06 | Herabstufung | Jefferies | Buy → Hold |
2020-10-19 | Eingeleitet | Truist | Buy |
2019-10-16 | Eingeleitet | Mizuho | Buy |
2018-11-19 | Eingeleitet | Leerink Partners | Outperform |
2018-10-08 | Hochstufung | B. Riley FBR | Neutral → Buy |
2018-08-08 | Eingeleitet | Robert W. Baird | Outperform |
2018-04-13 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Neutral |
2017-11-08 | Eingeleitet | Jefferies | Buy |
2017-05-30 | Eingeleitet | Chardan Capital Markets | Buy |
Alle ansehen
Assembly Biosciences Inc Aktie (ASMB) Neueste Nachrichten
Where are the Opportunities in (ASMB) - news.stocktradersdaily.com
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Down 47.1% in May - Defense World
Live Biotherapeutic Products and Microbiome CDMO Market Size to Hit USD 1,496.69 Mn by 2034 - Precedence Research
Assembly Biosciences (NASDAQ:ASMB) Stock Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Assembly Biosciences expands stock plans, appoints new CFO By Investing.com - Investing.com Nigeria
Assembly Biosciences expands stock plans, appoints new CFO - Investing.com
Assembly Biosciences Announces Stock Plan Amendments and Leadership Change - TipRanks
Assembly Biosciences IncJeanette M. Bjorkquist Appointed Principal Financial Officer On June 5- SEC Filing - MarketScreener
(ASMB) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Assembly Biosciences, Inc. (NASDAQ:ASMB) Shares Sold by Northern Trust Corp - Defense World
When Will Assembly Biosciences, Inc. (NASDAQ:ASMB) Breakeven? - Yahoo Finance
Assembly Biosciences, Inc. (NASDAQ:ASMB) Short Interest Up 99.2% in May - Defense World
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference | ASMB Stock News - GuruFocus
Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference - The Manila Times
Assembly Bio Leadership Team Set for Key Presentation at Major Jefferies Healthcare Conference - Stock Titan
Syndeio Biosciences Launches to Lead the Emerging Field of Synapse-Targeted Neurotherapeutics - Business Wire
Assembly’s NeosAI, Powered by Microsoft Azure AI Foundry, Sets New Benchmark for Legal Productivity—Backed by Real-World Results - GlobeNewswire Inc.
Mizuho Cuts Price Target on Assembly Biosciences to $29 From $36, Keeps Outperform Rating - marketscreener.com
ABI-4334 outperforms vebicorvir in HBV suppression - BioWorld MedTech
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates - MSN
Growth Investors: Industry Analysts Just Upgraded Their Assembly Biosciences, Inc. (NASDAQ:ASMB) Revenue Forecasts By 33% - simplywall.st
Assembly Biosciences First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Zacks Research Cuts Earnings Estimates for Las Vegas Sands - Defense World
Assembly Biosciences: Q1 Earnings Snapshot - New Haven Register
Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates - The Manila Times
Assembly Biosciences Reports Q1 2025 Earnings - TipRanks
Assembly Biosciences Inc (ASMB) Q1 2025 Earnings: EPS of -$1.17 Beats Estimate, Revenue of $9.4M Exceeds Forecast - GuruFocus
Assembly Biosciences Updates on Clinical Progress and Financials, Anticipates Key Data in 2025 - Nasdaq
Assembly Biosciences (ASMB) Highlights Promising Preclinical Data at EASL Congress | ASMB Stock News - GuruFocus
New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025 - The Manila Times
Ribbon Bio Launches MiroSynth™ DNA Molecules to Unlock a New Era of Complex Synthetic DNA - Yahoo Finance
Raymond James Financial Inc. Invests $973,000 in Invesco 0-5 Yr US TIPS ETF (BATS:PBTP) - The AM Reporter
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock? - NewsBreak: Local News & Alerts
Learn to Evaluate (ASMB) using the Charts - news.stocktradersdaily.com
JPMorgan Chase & Co. Acquires 7,918 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Assembly Biosciences Insiders Added US$679.4k Of Stock To Their Holdings - simplywall.st
Assembly Biosciences (NASDAQ:ASMB) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Renaissance Technologies LLC Boosts Stock Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Long Term Trading Analysis for (ASMB) - news.stocktradersdaily.com
Assembly Biosciences director sells $7,455 in stock - Investing.com Australia
Assembly Biosciences director sells $7,455 in stock By Investing.com - Investing.com South Africa
Takeda's ENTYVIO Continues Growth Trajectory in Ulcerative Colitis and Crohn's Disease | DelveInsight - PR Newswire UK
Assembly Biosciences Presents New Data Highlighting Long-Acting - GuruFocus
Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress - The Manila Times
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround - Yahoo Finance
ASMB stock touches 52-week low at $8.21 amid market challenges - Investing.com
Finanzdaten der Assembly Biosciences Inc-Aktie (ASMB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Assembly Biosciences Inc-Aktie (ASMB) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Bjorkquist Jeanette M | Principal Accounting Officer |
Mar 31 '25 |
Sale |
9.85 |
180 |
1,773 |
4,617 |
Okazaki Jason A | CEO and President |
Mar 31 '25 |
Sale |
9.85 |
355 |
3,496 |
14,757 |
White Nicole S | Chief Manufacturing Officer |
Mar 31 '25 |
Sale |
9.85 |
197 |
1,940 |
11,674 |
Houghton Michael | Director |
Dec 30 '24 |
Buy |
15.61 |
3,202 |
49,998 |
3,202 |
GILEAD SCIENCES, INC. | 10% Owner |
Dec 19 '24 |
Buy |
21.37 |
940,499 |
20,098,464 |
2,209,471 |
Schornstein Alexander | 10% Owner |
Nov 22 '24 |
Buy |
14.87 |
17,024 |
253,104 |
720,137 |
Schornstein Alexander | 10% Owner |
Nov 25 '24 |
Buy |
14.91 |
7,976 |
118,890 |
728,113 |
White Nicole S | Chief Manufacturing Officer |
Nov 18 '24 |
Sale |
16.29 |
40 |
652 |
11,871 |
Schornstein Alexander | 10% Owner |
Oct 08 '24 |
Buy |
14.58 |
10,000 |
145,800 |
703,113 |
White Nicole S | Chief Manufacturing Officer |
Oct 03 '24 |
Sale |
14.81 |
157 |
2,325 |
11,911 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):